Cencora posted third-quarter revenue of $84.8B, a 5.1% increase year-over-year. U.S. Healthcare Solutions contributed $74.9B. International Healthcare Solutions added $7.7B. GAAP diluted earnings per share reached $3.94, against an adjusted figure of $4.48. The adjusted metric climbed 12.0% year-over-year. The strategic question centers on how the OneOncology integration translates reported gross-profit expansion into durable operating leverage. Specialty distribution carries a structurally different margin profile than the legacy wholesale franchise. The scale of the underlying business gives Cencora a cost-of-capital advantage that is hard to replicate. The specialty pivot is the principal lever for re-rating the equity multiple over a multi-year horizon. Investors are looking for confirmation that the integration milestones land as expected in the back half of the year.
The company raised full-year adjusted EPS guidance to a range of $17.75 to $17.95. The prior range was slightly below the new midpoint. Net income attributable to Cencora reached $763.5M for the quarter. On a nine-month basis, net income hit $2.96B against $1.89B a year ago. Operating income expanded 29.1% to $1.1B. The OneOncology deal reshapes the U.S. mix toward higher-margin specialty distribution. Capital return remains a central pillar of the management team's capital-allocation framework. The active buyback program compresses the share count and provides a per-share tailwind. Adjusted EPS growth strips out non-recurring items to present a cleaner trend that aligns with management's long-term guidance framework.
Cencora closed the OneOncology acquisition in early February for $7.39B in total consideration. The closing followed a multi-month negotiation and shareholder approval process. Goodwill rose to $16.5B against $13.7B at the prior fiscal year end. The integration lifted U.S. segment gross profit by $565M in the quarter. The deal drove a 66-basis-point margin expansion to 4.26%. Cencora repurchased $1B of common stock during the third quarter. The forward setup blends mid-single-digit core growth with disciplined capital return. Balance-sheet absorption from the OneOncology deal remains a near-term overhang for the credit profile. The transaction marks a step-change in Cencora's positioning within the broader healthcare services value chain. Investor focus now shifts to integration milestones and the pace of MWI divestiture close.